Stratview Research has recently published a report on the Companion Diagnostics Market. This strategically evaluated report provides a detailed overview that presents today's market scenario and future possibilities, as well as market intelligence and information, for a 5-year period from 2022 to 2028.

The market is segmented by Technology Type (Immunohistochemistry, Polymerase Chain Reaction, Next Generation Sequencing, In Situ Hybridization, and Others), by Indication Type (Oncology [Lung Cancer, Colorectal Cancer, Breast Cancer, Blood Cancer, and Others], Neurology, and Others), and by Region (North America, Europe, Asia-Pacific, and Rest of the World).

Companion Diagnostics Market Analysis:

Stratview Research’s report discusses the segment-wise current market condition. Also, it offers an estimation of future growth opportunities. As per the estimation, the Companion Diagnostics Market was estimated to grow from USD 5.77 billion in 2021 to reach USD 13.55 billion by 2028 at a CAGR of 12.49% during the forecast period.

Some of the companies drive the market growth:

  • Abbott Laboratories Molecular, Inc.,
  • Agilent (Dako Denmark A/S),
  • ARUP Laboratories, Inc.,
  • BioMerieux, Danaher Corporation,
  • Foundation Medicine, Inc.,
  • Myriad Genetics, Inc.,
  • QIAGEN N.V.,
  • Roche (Ventana Medical Systems, Inc.),
  • Thermo Fisher Scientific (Life Technologies Corporation).

To download a free sample of the report, Click Here:

Segment Analysis

By Technology Type:

The market is segmented as immunohistochemistry, polymerase chain reaction, next generation sequencing, in situ hybridization, and others. The growth of the segment is owing to the cost effectiveness, high sensitivity, and specificity of polymerase chain reaction, as well as the fact that it can be used for simple automated platforms. Furthermore, PCR is used to determine the sequencing of unknown etiologies of many diseases, which fuels its growth over the forecast period.

Research Methodology

This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools.

More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles have been leveraged to gather the data.

We conducted more than 10 detailed primary interviews with the market players across the value chain in all four regions and with industry experts to obtain both qualitative and quantitative insights.

Custom Research: Stratview Research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at